# A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

> **NCT01005979** · PHASE1 · TERMINATED · sponsor: **Emory University** · enrollment: 6 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell
- Chronic Lymphocytic Leukemia
- Lymphoma, Small Lymphocytic

## Interventions

- **DRUG:** Lenalidomide, Rituximab, and Cyclophosphamide

## Key facts

- **NCT ID:** NCT01005979
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2012-10
- **Final completion:** —
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2014-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01005979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01005979, "A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01005979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*